Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Increase in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 11,000 shares, an increase of 15.8% from the November 15th total of 9,500 shares. Based on an average daily volume of 25,400 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.2% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a report on Monday, November 18th.

Aprea Therapeutics Stock Performance

Shares of APRE traded down $0.32 during trading hours on Friday, hitting $3.20. 25,108 shares of the company were exchanged, compared to its average volume of 20,368. The company has a market cap of $17.36 million, a PE ratio of -1.14 and a beta of 0.88. The firm’s 50 day moving average is $3.41 and its 200-day moving average is $3.60. Aprea Therapeutics has a 52 week low of $2.15 and a 52 week high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last announced its earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.11. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. The firm had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.45 million. As a group, equities analysts forecast that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Bernd R. Seizinger acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, October 11th. The shares were purchased at an average price of $2.68 per share, for a total transaction of $26,800.00. Following the completion of the acquisition, the director now owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. This represents a 28.79 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Marc Duey acquired 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The shares were acquired at an average cost of $4.39 per share, for a total transaction of $131,700.00. Following the transaction, the director now owns 240,113 shares of the company’s stock, valued at approximately $1,054,096.07. This represents a 14.28 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 42,290 shares of company stock worth $165,096. 12.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC bought a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics makes up 0.5% of Stonepine Capital Management LLC’s holdings, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned 2.53% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is owned by institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.